This excerpt taken from the AMLN 10-Q filed Jul 31, 2008.
Title: Specification for Placebo Exenatide Injection in Cartridges
Regulatory Specification for PBO-F12
Description: [***] containing [***]% (w/v) [***], [***]% (w/v) [***] in [***] mM [***], in 1.2, 2.4, or 3.0 mL cartridges
(a) [***] used at [***];
[***] may be used during [***].
* Confidential treatment request(ed).
This excerpt taken from the AMLN 10-K filed Feb 26, 2007.
Title. Title to all Pramlintide Acetate shall at all times remain in Company. Title to all Materials other than Pramlintide Acetate, work in progress to produce Product, and all completed Product (except Pramlintide Acetate contained therein) shall remain with Manufacturer until delivery of such Product to carrier designated by the Company. Notwithstanding the foregoing, and regardless of whether delivery of Product to Company has occurred under Section 5.1, Manufacturer shall bear all risk of loss with respect to, and shall insure, all Product until transfer by Manufacturer to a carrier for shipment as directed by Company in the applicable purchase order.